These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 26573597)
1. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Gevensleben H; Dietrich D; Golletz C; Steiner S; Jung M; Thiesler T; Majores M; Stein J; Uhl B; Müller S; Ellinger J; Stephan C; Jung K; Brossart P; Kristiansen G Clin Cancer Res; 2016 Apr; 22(8):1969-77. PubMed ID: 26573597 [TBL] [Abstract][Full Text] [Related]
2. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Ness N; Andersen S; Khanehkenari MR; Nordbakken CV; Valkov A; Paulsen EE; Nordby Y; Bremnes RM; Donnem T; Busund LT; Richardsen E Oncotarget; 2017 Apr; 8(16):26789-26801. PubMed ID: 28460462 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597 [TBL] [Abstract][Full Text] [Related]
4. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773 [TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma. Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403 [TBL] [Abstract][Full Text] [Related]
7. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients. Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860 [TBL] [Abstract][Full Text] [Related]
8. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759 [TBL] [Abstract][Full Text] [Related]
9. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901 [No Abstract] [Full Text] [Related]
10. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811 [TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362 [TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204 [TBL] [Abstract][Full Text] [Related]
13. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278 [TBL] [Abstract][Full Text] [Related]
14. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. Chang YL; Yang CY; Lin MW; Wu CT; Yang PC Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146 [TBL] [Abstract][Full Text] [Related]
15. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. Ishii H; Azuma K; Kawahara A; Yamada K; Imamura Y; Tokito T; Kinoshita T; Kage M; Hoshino T J Thorac Oncol; 2015 Mar; 10(3):426-30. PubMed ID: 25384063 [TBL] [Abstract][Full Text] [Related]
16. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840 [TBL] [Abstract][Full Text] [Related]
17. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569 [TBL] [Abstract][Full Text] [Related]
18. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Callea M; Albiges L; Gupta M; Cheng SC; Genega EM; Fay AP; Song J; Carvo I; Bhatt RS; Atkins MB; Hodi FS; Choueiri TK; McDermott DF; Freeman GJ; Signoretti S Cancer Immunol Res; 2015 Oct; 3(10):1158-64. PubMed ID: 26014095 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status. Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193 [TBL] [Abstract][Full Text] [Related]
20. Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker? Mukherji D; Jabbour MN; Saroufim M; Temraz S; Nasr R; Charafeddine M; Assi R; Shamseddine A; Tawil AN Clin Genitourin Cancer; 2016 Apr; 14(2):183-7. PubMed ID: 26775720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]